Division of Haematology and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Perugia, Ospedale Santa Maria della Misericordia, 06132 - Perugia, Italy.
Curr Opin Immunol. 2009 Oct;21(5):525-30. doi: 10.1016/j.coi.2009.07.015. Epub 2009 Aug 28.
Donor-versus-recipient natural killer (NK) cell alloreactivity has been established as a key therapeutic element in HLA haplotype mismatched hematopoietic transplants in adult AML and pediatric ALL and as a possible beneficial effector in cord blood transplant for AML. It is effected by functional NK cells which express inhibitory killer cell immunoglobulin-like receptor(s) (KIR) for self-class I ligand(s), sense missing expression of donor KIR ligand(s) in the recipient and mediate alloreactions. At present NK cell allotherapy for leukemia is deployed through stem cell transplantation (and ensuing NK cell reconstitution) across KIR ligand mismatches. Studies have been performed to infuse NK cells for immunotherapy outside the fields of transplantation and/or harness the function of endogenous NK cells in patients with hematological malignancies.
供者与受者自然杀伤 (NK) 细胞同种反应已被确立为成人 AML 和儿科 ALL 中 HLA 单倍型错配造血移植的关键治疗因素，并且作为 AML 脐血移植中可能有益的效应物。它是由表达抑制性杀伤细胞免疫球蛋白样受体 (KIR) 的功能性 NK 细胞来实现的，这些受体识别自身 I 类配体，感知受者中供者 KIR 配体的缺失表达，并介导同种反应。目前，用于白血病的 NK 细胞过继疗法是通过干细胞移植（随之而来的 NK 细胞重建）在 KIR 配体错配的情况下进行的。已经进行了一些研究，以在移植领域之外输注 NK 细胞进行免疫治疗，和/或利用血液恶性肿瘤患者内源性 NK 细胞的功能。
